Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma

Federica Perrone, Genny Jocoll, Marzia Pennati, Marcello Deraco, Dario Baratti, Silvia Brich, Marta Orsenigo, Eva Tarantino, Cinzia De Marco, Claudia Bertan, Antonello Cabras, Rossella Bertulli, Marco Alessandro Pierotti, Nadia Zaffaroni, Silvana Pilotti

Research output: Contribution to journalArticle

Abstract

Our aim was to assess the activation profile of EGFR, PDGFRB and PDGFRA receptor tyrosine kinases (RTK) and their downstream effectors in a series of cryopreserved diffuse malignant peritoneal mesothelioma (DMPM) surgical specimens to discover the targets for drug inhibition. We also made a complementary analysis of the cytotoxic effects of some kinase inhibitors on the proliferation of the human peritoneal mesothelioma STO cell line. We found the expression/phosphorylation of EGFR and PDGFRB in most of the tumours, and PDGFRA activation in half. The expression of the cognate ligands TGF-α, PDGFB and PDGFA in the absence of RTK mutation and amplification suggested the presence of an autocrine/paracrine loop. There was also evidence of EGFR and PDGFRB co-activation. RTK downstream signalling analysis demonstrated the activation/expression of ERK1/2, AKT and mTOR, together with S6 and 4EBP1, in almost all the DMPMs. No KRAS/BRAF mutations, PI3KCA mutations/amplifications or PTEN inactivation were observed. Real-time polymerase chain reaction revealed the decreased expression of TSC1 c-DNA in half of the tumours. In vitro cytotoxicity studies showed the STO cell line to be resistant to gefitinib and sensitive to sequential treatment with RAD001 and sorafenib; these findings were consistent with the presence of the KRAS mutation G12D in these cells although it was not detectable in the original tumour. Our results highlight the ligand-dependent activation and co-activation of EGFR and PDGFRB, as well as a connection between these activated RTKs and the downstream mTOR pathway, thus supporting the role of combined treatment with RTK and mTOR inhibitors in DMPM.

Original languageEnglish
Pages (from-to)2837-2848
Number of pages12
JournalEuropean Journal of Cancer
Volume46
Issue number15
DOIs
Publication statusPublished - Oct 2010

Fingerprint

Platelet-Derived Growth Factor beta Receptor
Receptor Protein-Tyrosine Kinases
Mutation
Proto-Oncogene Proteins c-sis
Ligands
Activation Analysis
S 6
Cell Line
Neoplasms
Mesothelioma
Real-Time Polymerase Chain Reaction
Phosphotransferases
Phosphorylation
Malignant Mesothelioma
DNA
Pharmaceutical Preparations

Keywords

  • Diffuse malignant peritoneal mesothelioma
  • EGFR
  • mTOR
  • p16
  • PDGFRB

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma. / Perrone, Federica; Jocoll, Genny; Pennati, Marzia; Deraco, Marcello; Baratti, Dario; Brich, Silvia; Orsenigo, Marta; Tarantino, Eva; De Marco, Cinzia; Bertan, Claudia; Cabras, Antonello; Bertulli, Rossella; Pierotti, Marco Alessandro; Zaffaroni, Nadia; Pilotti, Silvana.

In: European Journal of Cancer, Vol. 46, No. 15, 10.2010, p. 2837-2848.

Research output: Contribution to journalArticle

Perrone, Federica ; Jocoll, Genny ; Pennati, Marzia ; Deraco, Marcello ; Baratti, Dario ; Brich, Silvia ; Orsenigo, Marta ; Tarantino, Eva ; De Marco, Cinzia ; Bertan, Claudia ; Cabras, Antonello ; Bertulli, Rossella ; Pierotti, Marco Alessandro ; Zaffaroni, Nadia ; Pilotti, Silvana. / Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma. In: European Journal of Cancer. 2010 ; Vol. 46, No. 15. pp. 2837-2848.
@article{ab45c3ffabc44e47bc05cf68b17bc036,
title = "Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma",
abstract = "Our aim was to assess the activation profile of EGFR, PDGFRB and PDGFRA receptor tyrosine kinases (RTK) and their downstream effectors in a series of cryopreserved diffuse malignant peritoneal mesothelioma (DMPM) surgical specimens to discover the targets for drug inhibition. We also made a complementary analysis of the cytotoxic effects of some kinase inhibitors on the proliferation of the human peritoneal mesothelioma STO cell line. We found the expression/phosphorylation of EGFR and PDGFRB in most of the tumours, and PDGFRA activation in half. The expression of the cognate ligands TGF-α, PDGFB and PDGFA in the absence of RTK mutation and amplification suggested the presence of an autocrine/paracrine loop. There was also evidence of EGFR and PDGFRB co-activation. RTK downstream signalling analysis demonstrated the activation/expression of ERK1/2, AKT and mTOR, together with S6 and 4EBP1, in almost all the DMPMs. No KRAS/BRAF mutations, PI3KCA mutations/amplifications or PTEN inactivation were observed. Real-time polymerase chain reaction revealed the decreased expression of TSC1 c-DNA in half of the tumours. In vitro cytotoxicity studies showed the STO cell line to be resistant to gefitinib and sensitive to sequential treatment with RAD001 and sorafenib; these findings were consistent with the presence of the KRAS mutation G12D in these cells although it was not detectable in the original tumour. Our results highlight the ligand-dependent activation and co-activation of EGFR and PDGFRB, as well as a connection between these activated RTKs and the downstream mTOR pathway, thus supporting the role of combined treatment with RTK and mTOR inhibitors in DMPM.",
keywords = "Diffuse malignant peritoneal mesothelioma, EGFR, mTOR, p16, PDGFRB",
author = "Federica Perrone and Genny Jocoll and Marzia Pennati and Marcello Deraco and Dario Baratti and Silvia Brich and Marta Orsenigo and Eva Tarantino and {De Marco}, Cinzia and Claudia Bertan and Antonello Cabras and Rossella Bertulli and Pierotti, {Marco Alessandro} and Nadia Zaffaroni and Silvana Pilotti",
year = "2010",
month = "10",
doi = "10.1016/j.ejca.2010.06.130",
language = "English",
volume = "46",
pages = "2837--2848",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "15",

}

TY - JOUR

T1 - Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma

AU - Perrone, Federica

AU - Jocoll, Genny

AU - Pennati, Marzia

AU - Deraco, Marcello

AU - Baratti, Dario

AU - Brich, Silvia

AU - Orsenigo, Marta

AU - Tarantino, Eva

AU - De Marco, Cinzia

AU - Bertan, Claudia

AU - Cabras, Antonello

AU - Bertulli, Rossella

AU - Pierotti, Marco Alessandro

AU - Zaffaroni, Nadia

AU - Pilotti, Silvana

PY - 2010/10

Y1 - 2010/10

N2 - Our aim was to assess the activation profile of EGFR, PDGFRB and PDGFRA receptor tyrosine kinases (RTK) and their downstream effectors in a series of cryopreserved diffuse malignant peritoneal mesothelioma (DMPM) surgical specimens to discover the targets for drug inhibition. We also made a complementary analysis of the cytotoxic effects of some kinase inhibitors on the proliferation of the human peritoneal mesothelioma STO cell line. We found the expression/phosphorylation of EGFR and PDGFRB in most of the tumours, and PDGFRA activation in half. The expression of the cognate ligands TGF-α, PDGFB and PDGFA in the absence of RTK mutation and amplification suggested the presence of an autocrine/paracrine loop. There was also evidence of EGFR and PDGFRB co-activation. RTK downstream signalling analysis demonstrated the activation/expression of ERK1/2, AKT and mTOR, together with S6 and 4EBP1, in almost all the DMPMs. No KRAS/BRAF mutations, PI3KCA mutations/amplifications or PTEN inactivation were observed. Real-time polymerase chain reaction revealed the decreased expression of TSC1 c-DNA in half of the tumours. In vitro cytotoxicity studies showed the STO cell line to be resistant to gefitinib and sensitive to sequential treatment with RAD001 and sorafenib; these findings were consistent with the presence of the KRAS mutation G12D in these cells although it was not detectable in the original tumour. Our results highlight the ligand-dependent activation and co-activation of EGFR and PDGFRB, as well as a connection between these activated RTKs and the downstream mTOR pathway, thus supporting the role of combined treatment with RTK and mTOR inhibitors in DMPM.

AB - Our aim was to assess the activation profile of EGFR, PDGFRB and PDGFRA receptor tyrosine kinases (RTK) and their downstream effectors in a series of cryopreserved diffuse malignant peritoneal mesothelioma (DMPM) surgical specimens to discover the targets for drug inhibition. We also made a complementary analysis of the cytotoxic effects of some kinase inhibitors on the proliferation of the human peritoneal mesothelioma STO cell line. We found the expression/phosphorylation of EGFR and PDGFRB in most of the tumours, and PDGFRA activation in half. The expression of the cognate ligands TGF-α, PDGFB and PDGFA in the absence of RTK mutation and amplification suggested the presence of an autocrine/paracrine loop. There was also evidence of EGFR and PDGFRB co-activation. RTK downstream signalling analysis demonstrated the activation/expression of ERK1/2, AKT and mTOR, together with S6 and 4EBP1, in almost all the DMPMs. No KRAS/BRAF mutations, PI3KCA mutations/amplifications or PTEN inactivation were observed. Real-time polymerase chain reaction revealed the decreased expression of TSC1 c-DNA in half of the tumours. In vitro cytotoxicity studies showed the STO cell line to be resistant to gefitinib and sensitive to sequential treatment with RAD001 and sorafenib; these findings were consistent with the presence of the KRAS mutation G12D in these cells although it was not detectable in the original tumour. Our results highlight the ligand-dependent activation and co-activation of EGFR and PDGFRB, as well as a connection between these activated RTKs and the downstream mTOR pathway, thus supporting the role of combined treatment with RTK and mTOR inhibitors in DMPM.

KW - Diffuse malignant peritoneal mesothelioma

KW - EGFR

KW - mTOR

KW - p16

KW - PDGFRB

UR - http://www.scopus.com/inward/record.url?scp=77957203611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957203611&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2010.06.130

DO - 10.1016/j.ejca.2010.06.130

M3 - Article

C2 - 20692828

AN - SCOPUS:77957203611

VL - 46

SP - 2837

EP - 2848

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 15

ER -